SAN DIEGO – March 17, 2016 – Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced that members of the management team will present at the 9th Annual Oncology Commercialization & Market Access meeting, to be held March 22-23 in San Francisco; participate in a panel discussion at the Cancer Advance Boston conference, to be held April 4-5 in Boston; and present at the Phacilitate Oncology Leaders Forum, to be held April 5-6 in Boston.
Details of the presentations are as follows:
Conference: 9th Annual Oncology Commercialization & Market Access meeting
Title: Examine a Biotech’s Pathway Towards First Product Launch — From Early Grass Roots Efforts to Pre-launch Planning
Date and Time: Tuesday, March 22, 4:30-5:15 p.m. PT
Presenter: Nicholas Boyle, Ph.D., product manager and head of business development at Tocagen
Conference: Cancer Advance Boston
Panel Title: Checkpoint Inhibitors: What’s New?
Date and Time: Tuesday, April 5, 9:50-10:30 a.m. ET
Participant: Harry Gruber, M.D., chief executive officer of Tocagen
Conference: Phacilitate Oncology Leaders Forum
Title: Viral immunotherapy as a novel therapeutic modality: mechanisms and clinical utility
Date and Time: Wednesday, April 6, 2:20-2:35 p.m. ET
Presenter: Douglas Jolly, Ph.D., executive vice president of research and pharmaceutical development at Tocagen
Tocagen is a clinical-stage, cancer-selective gene therapy company focused on developing first-in-class, broadly applicable product candidates designed to activate a patient’s immune system against their own cancer from within. The company is developing its lead investigational product candidate, Toca 511 (vocimagene amiretrorepvec) & Toca FC (extended-release 5-fluorocytosine), initially for the treatment of recurrent high grade glioma (HGG), a disease with significant unmet medical need. Tocagen has initiated the Phase 2 portion of a randomized, controlled Phase 2/3 clinical trial of Toca 511 & Toca FC in patients with recurrent HGG, which is designed to serve as a potential registrational trial. More information about the clinical trial can be found at www.tocagen.com/toca5. In 2016, Tocagen plans to initiate clinical trials of Toca 511 & Toca FC in patients with newly diagnosed HGG and other solid tumors. Tocagen obtained Fast Track designation from the U.S. Food and Drug Administration, for Toca 511 & Toca FC for the treatment of recurrent HGG and Orphan drug designation for the treatment of glioblastoma (GBM), a subset of HGG. Tocagen has received grant support from leading brain cancer foundations, including Accelerate Brain Cancer Cure (ABC2), National Brain Tumor Society (NBTS), American Brain Tumor Association (ABTA), Musella Foundation and Voices Against Brain Cancer (VABC). For more information visit www.tocagen.com or follow @Tocagen.